BGMA Warns Over US Trade Deal
UK Must Not Put NHS At Risk, Association Says
Warwick Smith, director general of the British Generic Manufacturers Association, has warned of increased costs and risks to the NHS due to intellectual property requirements sought by the US as part of a free trade agreement with the UK.
You may also be interested in...
Stada has appointed general managers for its businesses in Germany and Poland. Meanwhile, US and UK industry associations the AAM and BGMA have announced appointments, Glenmark has added an ex-Teva executive to its board of directors and the MHRA has named a new chair.
Responding to UK government statements on the country’s future approach to trade deals with non-EU nations, the BGMA has insisted that there must be no changes to patent and exclusivity provisions that would block market entry for generic and biosimilar medicines.
On the eve of the UK’s formal exit from the EU on 31 January, BGMA director general Warwick Smith has insisted that it is essential for the UK to stay as close as possible to the current European medicines framework following the conclusion of a transition period that is currently due to expire at the end of 2020.